http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_91c91da5ecdf09e1f17789596bddb3d2
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Janku |
| name | Filip Janku |
| given-name | Filip |
| organization-name | Anita Chawla, Zhou Zhou, and James Signorovitch, Analysis Group, Boston; Vincent A. Miller, Jason Ryan, and Rachel Anhorn, Foundation Medicine, Cambridge, MA; and Filip Janku and Jennifer J. Wheler, The University of Texas MD Anderson Cancer Center, Houston, TX. Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center , Houston, TX , USA Authors' Affiliation: Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), The University of Texas, M.D. Anderson Cancer Center, Houston, Texas 10Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Authors' Affiliations: 1Departments of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, and 3Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas 20Department of Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. David Hong, Filip Janku, Ly M. Nguyen, Aung Naing, Sarina Piha-Paul, Faye M. Johnson, and Razelle Kurzrock, The University of Texas MD Anderson Cancer Center, Houston, TX; Jeffrey Infante, Suzanne Jones, Howard A. Burris, Todd M. Bauer, and Johanna Bendell, Sarah Cannon Research Institute; Jeffrey Infante, Howard A. Burris, Todd M. Bauer, and Johanna Bendell, Tennessee Oncology, Nashville, TN; and Lisa Golden, Scott Hynes, Ji Lin, and Aimee Bence Lin, Eli Lilly, Indianapolis, IN. 3The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX; and Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX; MD Anderson Cancer Center, Houston, TX, USA Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Phase I Clinical Trials Program, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX Department of Investigational Cancer Therapeutics The University of Texas MD Anderson Cancer Center Houston Texas Department of Investigational Cancer Therapeutics (Phase I Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 1Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Investigational Cancer Therapeutics Houston Texas USA Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, and 3Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas a Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Division of Cancer Medicine Department of Investigational Cancer Therapeutics The University of Texas MD Anderson Cancer Center Houston Texas Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center All authors: The University of Texas MD Anderson Cancer Center, Houston, TX. Dejan Juric, Massachusetts General Hospital Cancer Center, Boston; Alan Huang, Novartis Institutes for BioMedical Research, Cambridge, MA; Jordi Rodon and Josep Tabernero, Vall d’Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona; Marta Gil-Martin, Catalan Institute of Oncology - Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain; Filip Janku, The University of Texas MD Anderson Cancer Center, Houston, TX; Howard A. Burris, Sarah Cannon Research... 1Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, Texas. Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center , Houston , USA Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, 3Gastrointestinal Medical Oncology, and 4Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 5Moores Cancer Center, The University of California San Diego, La Jolla, California Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Investigational Cancer Therapeutics (Phase I Program), U.T. MD Anderson Cancer Center, Houston, TX The University of Texas MD Anderson Cancer Center, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 1515 Holcombe Boulevard 0455, Houston, Texas 77030, United States 1Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas. Departments of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Departments of Investigational Cancer Therapeutics (Phase I Clinical Trials Program) and Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas 5The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA Department of Investigational Cancer Therapeutics - a Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Texas Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, FC8.2018, Box 0455, Houston, TX 77030, USA Invest. Cancer Therapeutics, and 2Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Investigational Cancer Therapeutics Department of Investigational Cancer Therapeutics The University of Texas MD Anderson Cancer Center Houston TX Department of Investigational Cancer Therapeutics The University of Texas MD Anderson Cancer Center Houston Texas USA University College Cork, Bon Secours Hospital, College Road, Cork, Ireland Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX Authors' Affiliations: 1Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Department of Biostatistics, and 3Molecular Diagnostic Laboratory, The University of Texas M.D. Anderson Cancer Center, Houston, Texas Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030 Sigurdis Haraldsdottir, Ming Poi, Cynthia Timmers, Susan Geyer, Larry J. Schaaf, Jennifer Sexton, Lai Wei, Jennifer Thurmond, Erin M. Bertino, Kari Kendra, Amir Mortazavi, Mitch Phelps, and Manisha H. Shah, Ohio State University Medical Center, Columbus, OH; Sigurdis Haraldsdottir, Stanford University, Stanford, CA; Filip Janku, Vivianne Velez-Bravo, Vanda M. Stepanek, and Vivek Subbiah, University of Texas MD Anderson Cancer Center, Houston, TX; and Susan Geyer, University of South Florida, Tampa, FL. Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Department of Investigational Cancer Therapeutics - a Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center University of Texas MD Anderson Cancer Center, Houston, TX, USA 3Charles University, Prague, Czech Republic; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA 16The University of Texas MD Anderson Cancer Center; 5Department of Investigational Cancer Therapeutics (Phase I Program), The MD Anderson Cancer Center, Houston, Texas. Department of Investigational Cancer Therapeutics (A Phase I Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA Department of Pathology The University of Texas MD Anderson Cancer Center Houston Texas; Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program) The University of Texas MD Anderson Cancer Center Houston Texas 1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, FC8.2018, Box 0455, Houston, TX 77030, USA Scott Kopetz, Dipen Maru, Van Morris, Filip Janku, and Arvind Dasari, The University of Texas MD Anderson Cancer Center, Houston, TX; Emily Chan, Vanderbilt-Ingram Cancer Center, Nashville, TN; Joel Randolph Hecht, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles; Brian James and Garth Powis, Sanford Burnham Institute, La Jolla; Keith B. Nolop, Plexxikon, Berkeley; Suman Bhattacharya, Genentech, South San Francisco, CA; Peter J. O'Dwyer, Abramson Cancer Center at... Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Apostolia-Maria Tsimberidou, David S. Hong, Yang Ye, Carrie Cartwright, Jennifer J. Wheler, Gerald S. Falchook, Aung Naing, Siqing Fu, Sarina Piha-Paul, Filip Janku, Funda Meric-Bernstam, Patrick Hwu, Bryan Kee, Merrill S. Kies, Russell Broaddus, John Mendelsohn, and Kenneth R. Hess, The University of Texas MD Anderson Cancer Center, Houston, TX; and Razelle Kurzrock, University of California, San Diego, San Diego, CA. Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX a Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 6Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. The University of Texas MD Anderson Cancer Center, Houston, TX Investigational Cancer Therapeutics (a phase I program), University of Texas M. D. Anderson Cancer Center, Houston, TX 3Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas. Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, and 3Head and Neck, The University of Texas M.D. Anderson Cancer Center, Houston, Texas Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA Department of Investigational Cancer Therapeutics – a Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center Houston, Texas, USA Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Authors' Affiliations: Departments of 1Gynecology and 2Investigational Cancer Therapeutics (A Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, Texas; and 3Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Wright State University Boonshoft School of Medicine, Dayton, Ohio Authors' Affiliations: 1Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program; and Departments of 2Hematopathology and 3Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 1Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, Texas. Vivek Subbiah, Shiraj Sen, Kenneth R. Hess, Filip Janku, David S. Hong, Soumen Khatua, Daniel D. Karp, Javier Munoz, Roman Groisberg, Apostolia M. Tsimberidou, Steven I. Sherman, Patrick Hwu, and Funda Meric-Bernstam, The University of Texas MD Anderson Cancer Center, Houston, TX; and Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO. 2Department of Investigational Cancer Therapeutics – a Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas. Investigational Cancer Therapeutics (Phase I Trials Program), The University of Texas MD Anderson Cancer Center, Houston Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Department of Oncology, First Faculty of Medicine, General Teaching Hospital, Charles University. U Nemocnice 2, 128 08 Praha 2, Czech Republic. The University of Texas M. D. Anderson Cancer Center, Houston, TX |
Incoming Links
Showing number of triples: 1 to 340 of 340.